Seattle-based Omeros reported Wednesday that the firm has gained $3.1M in a second tranche of equity and grant funding, for the firm's candidates for the treatment of schizophrenia. The firm said the funding came from The Stanley Medical Research Institute (SMRI). The firm said it may receive up to $9M in grant and equity funding from SMRI, as part of a December 2006 agreement it has with SMRI to develop its PDE10 candidates. The firm already received $2.6M from SMRI. Omeros said the new milestone payment came after the firm successfully met preclinical compound optimization criteria.